



ASX ANNOUNCEMENT

FebriDx to Support University of Wollongong's Antimicrobial Stewardship in General Practice Trial

Key Highlights

- **FebriDx to be used in the University of Wollongong's OPTIMAS-GP Trial - aiming to reduce unnecessary antibiotic prescribing for respiratory infections in primary care settings**
- **FebriDx tests to be provided as one of a suite of interventions being assessed**
- **The first Australian study to use FebriDx in a General Practice primary care setting**

MELBOURNE, Australia (17 June 2025) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that its FebriDx® point-of-care test will be used as part of a major antimicrobial stewardship implementation trial to be conducted over five years and led by the University of Wollongong ("UOW"). The project, titled the Optimal Implementation of Antimicrobial Stewardship in General Practice ("OPTIMAS-GP") Trial, aims to reduce inappropriate antibiotic prescribing in Australian primary care.

Led by Professor Andrew Bonney and a team of researchers at UOW's Graduate School of Medicine, the study focuses on practical, evidence-based strategies to safely reduce unnecessary antibiotic use for respiratory tract infections in general practice.

Antimicrobial resistance ("AMR") - the ability of microbes to resist the effects of medication - poses a growing threat to global health. A significant contributor to this crisis is the inappropriate prescribing of antibiotics, particularly for acute respiratory infections in primary care settings.

The trial, funded with \$2.7 million from the Australian Government's Medical Research Future Fund (MRFF), as announced on 17 April 2024, has confirmed that it will commence using FebriDx from July 2026 for a period of approximately 5 months. Lumos Diagnostics will be providing approximately 2,000 FebriDx test kits to the study at a reduced cost. Lumos is not a sponsor of the project, and FebriDx is one of a suite of interventions being assessed. As part of this trial, FebriDx will be evaluated for its acceptability and feasibility for use in Australian general practice to support appropriate antibiotic prescribing in acute respiratory infection cases.

FebriDx is a rapid point-of-care test that differentiates between viral and bacterial acute respiratory infections, allowing clinicians to make more informed prescribing decisions. This will be the first time FebriDx is formally evaluated in an Australian primary care setting.

Andrew Bonney, Roberta Williams Chair of General Practice, University of Wollongong, commented: "General practitioners are at the forefront of combating antimicrobial resistance in Australia. We are excited about the potential of the OPTIMAS-GP Trial to assist GPs in this important role, and pleased to be evaluating the implementation of FebriDx, among other interventions, to promote evidence-based GP anti-microbial stewardship."

Doug Ward, Managing Director of Lumos Diagnostics, commented: *"We are pleased to be supporting this important initiative aimed at reducing inappropriate antibiotic use and combating antimicrobial resistance. Participating in the OPTIMAS-GP Trial reflects our commitment to equipping healthcare professionals with tools that promote evidence-based clinical decisions and better patient outcomes."*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About University of Wollongong

The University of Wollongong was born 50 years ago with a mission to transform our region and to educate and empower the people of the Illawarra. Our commitment to a better future has shaped our direction since our inception. Ranked in the top 1 per cent of universities worldwide, we have become globally recognised for the impact of our research, the strength of our teaching and the quality of our graduates. As we celebrate the accomplishments of the past five decades, we remain focused on delivering a more sustainable and equitable future for all.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

George Kopsiaftis
IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000 Australia
+61 3 9087 1598